BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

604 related articles for article (PubMed ID: 30458197)

  • 1. Heterogeneous mutational profile and prognosis conferred by TP53 mutations in appendiceal mucinous neoplasms.
    Zhu X; Salhab M; Tomaszewicz K; Meng X; Mathew C; Bathini V; Switzer B; Walter O; Cosar EF; Wang X; Lambert LA; Hutchinson LM
    Hum Pathol; 2019 Mar; 85():260-269. PubMed ID: 30458197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A mutation spectrum that includes GNAS, KRAS and TP53 may be shared by mucinous neoplasms of the appendix.
    Hara K; Saito T; Hayashi T; Yimit A; Takahashi M; Mitani K; Takahashi M; Yao T
    Pathol Res Pract; 2015 Sep; 211(9):657-64. PubMed ID: 26160192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular and clinicopathological features of appendiceal mucinous neoplasms.
    Yanai Y; Saito T; Hayashi T; Akazawa Y; Yatagai N; Tsuyama S; Tomita S; Hirai S; Ogura K; Matsumoto T; Wada R; Yao T
    Virchows Arch; 2021 Mar; 478(3):413-426. PubMed ID: 32821969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation profile of high-grade appendiceal mucinous neoplasm.
    Liao X; Vavinskaya V; Sun K; Hao Y; Li X; Valasek M; Xu R; Polydorides AD; Houldsworth J; Harpaz N
    Histopathology; 2020 Feb; 76(3):461-469. PubMed ID: 31491041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathologic and molecular analysis of disseminated appendiceal mucinous neoplasms: identification of factors predicting survival and proposed criteria for a three-tiered assessment of tumor grade.
    Davison JM; Choudry HA; Pingpank JF; Ahrendt SA; Holtzman MP; Zureikat AH; Zeh HJ; Ramalingam L; Zhu B; Nikiforova M; Bartlett DL; Pai RK
    Mod Pathol; 2014 Nov; 27(11):1521-39. PubMed ID: 24633196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GNAS is frequently mutated in both low-grade and high-grade disseminated appendiceal mucinous neoplasms but does not affect survival.
    Singhi AD; Davison JM; Choudry HA; Pingpank JF; Ahrendt SA; Holtzman MP; Zureikat AH; Zeh HJ; Ramalingam L; Mantha G; Nikiforova M; Bartlett DL; Pai RK
    Hum Pathol; 2014 Aug; 45(8):1737-43. PubMed ID: 24925222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular profiling of appendiceal epithelial tumors using massively parallel sequencing to identify somatic mutations.
    Liu X; Mody K; de Abreu FB; Pipas JM; Peterson JD; Gallagher TL; Suriawinata AA; Ripple GH; Hourdequin KC; Smith KD; Barth RJ; Colacchio TA; Tsapakos MJ; Zaki BI; Gardner TB; Gordon SR; Amos CI; Wells WA; Tsongalis GJ
    Clin Chem; 2014 Jul; 60(7):1004-11. PubMed ID: 24821835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung.
    Shim HS; Kenudson M; Zheng Z; Liebers M; Cha YJ; Hoang Ho Q; Onozato M; Phi Le L; Heist RS; Iafrate AJ
    J Thorac Oncol; 2015 Aug; 10(8):1156-62. PubMed ID: 26200269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discrimination of low- and high-grade appendiceal mucinous neoplasms by targeted sequencing of cancer-related variants.
    LaFramboise WA; Pai RK; Petrosko P; Belsky MA; Dhir A; Howard PG; Becich MJ; Holtzman MP; Ahrendt SA; Pingpank JF; Zeh HJ; Dhir R; Bartlett DL; Choudry HA
    Mod Pathol; 2019 Jul; 32(8):1197-1209. PubMed ID: 30962504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
    Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS
    BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer.
    Tokunaga R; Xiu J; Johnston C; Goldberg RM; Philip PA; Seeber A; Naseem M; Lo JH; Arai H; Battaglin F; Puccini A; Berger MD; Soni S; Zhang W; Hwang JJ; Shields AF; Marshall JL; Baba H; Korn WM; Lenz HJ
    Clin Cancer Res; 2019 May; 25(10):3096-3103. PubMed ID: 30692096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS and GNAS Co-Mutation in Metastatic Low-Grade Appendiceal Mucinous Neoplasm (LAMN) to the Ovaries: A Practical Role for Next-Generation Sequencing.
    Matson DR; Xu J; Huffman L; Barroilhet L; Accola M; Rehrauer WM; Weisman P
    Am J Case Rep; 2017 May; 18():558-562. PubMed ID: 28526814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients.
    Sclafani F; Wilson SH; Cunningham D; Gonzalez De Castro D; Kalaitzaki E; Begum R; Wotherspoon A; Capdevila J; Glimelius B; Roselló S; Thomas J; Tait D; Brown G; Oates J; Chau I
    Int J Cancer; 2020 Jan; 146(1):94-102. PubMed ID: 31199501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular profiling of appendiceal serrated lesions, polyps and mucinous neoplasms: a single-centre experience.
    Munari G; Businello G; Mattiolo P; Pennelli G; Sbaraglia M; Borga C; Pucciarelli S; Spolverato G; Mescoli C; Galuppini F; Sommariva A; Bellan E; Lonardi S; Loupakis F; Luchini C; Dei Tos AP; Fassan M
    J Cancer Res Clin Oncol; 2021 Jul; 147(7):1897-1904. PubMed ID: 33712927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential protein immunoexpression profiles in appendiceal mucinous neoplasms: a special reference to classification and predictive factors.
    Yoon SO; Kim BH; Lee HS; Kang GH; Kim WH; Kim YA; Kim JE; Chang MS
    Mod Pathol; 2009 Aug; 22(8):1102-12. PubMed ID: 19448592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colorectal carcinomas with mucinous differentiation are associated with high frequent mutation of KRAS or BRAF mutations, irrespective of quantity of mucinous component.
    Li X; Sun K; Liao X; Gao H; Zhu H; Xu R
    BMC Cancer; 2020 May; 20(1):400. PubMed ID: 32384877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
    van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
    Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.
    Meagher NS; Schuster K; Voss A; Budden T; Pang CNI; deFazio A; Ramus SJ; Friedlander ML
    Gynecol Oncol; 2018 Sep; 150(3):527-533. PubMed ID: 30054102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular and Genetic Markers in Appendiceal Mucinous Tumors: A Systematic Review.
    Stein A; Strong E; Clark Gamblin T; Clarke C; Tsai S; Thomas J; George B; Mogal H
    Ann Surg Oncol; 2020 Jan; 27(1):85-97. PubMed ID: 31583543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.